DEUTERIUM-ENRICHED DISUFENTON

1 . A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 15 are independently selected from H and D; and the abundance of deuterium in R 1 -R 15 is at least 7%.

2 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 15 is selected from at least 7%, at least 8%, at least 12%, at least 16%, at least 20%, at least 27%, at least 28%, at least 32%, at least 36%, at least 40%, at least 47%, at least 48%, at least 52%, at least 56%, at least 60%, at least 67%, at least 68%, at least 72%, at least 76%, at least 80%, at least 87%, at least 88%, at least 92%, at least 96%, and 100%.

3 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 3 is selected from at least 33%, at least 67%, and 100%.

4 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 4 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

5 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 5 -R 13 is selected from at least 11%, at least 22%, at least 33%, at least 44%, at least 56%, at least 67%, at least 78%, 100%.

6 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 14 -R 15 is selected from at least 50% and 100%.

7 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 1-5 of Table 1.

8 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 6-10 of Table 2.

9 . An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 15 are independently selected from H and D; and the abundance of deuterium in R 1 -R 15 is at least 7%.

10 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 1 -R 15 is selected from at least 7%, at least 8%, at least 12%, at least 16%, at least 20%, at least 27%, at least 28%, at least 32%, at least 36%, at least 40%, at least 47%, at least 48%, at least 52%, at least 56%, at least 60%, at least 67%, at least 68%, at least 72%, at least 76%, at least 80%, at least 87%, at least 88%, at least 92%, at least 96%, and 100%.

11 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 1 -R 3 is selected from at least 33%, at least 67%, and 100%.

12 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 4 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

13 . An isolated deuterium-enriched compound of claim 9 , wherein the abundance of deuterium in R 5 -R 13 is selected from at least 11%, at least 22%, at least 33%, at least 44%, at least 56%, at least 67%, at least 78%, 100%.

14 . An isolated deuterium-enriched compound of claim 9 , wherein the compound is selected from compounds 1-5 of Table 1.

15 . An isolated deuterium-enriched compound of claim 9 , wherein the compound is selected from compounds 6-10 of Table 2.

16 . A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 15 are independently selected from H and D; and the abundance of deuterium in R 1 -R 15 is at least 7%.

17 . A mixture of deuterium-enriched compounds of claim 16 , wherein the compound is selected from compounds 1-5 of Table 1.

18 . A mixture of deuterium-enriched compounds of claim 16 , wherein the compound is selected from compounds 6-10 of Table 2.

19 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

20 . A method for treating acute ischaemic stroke comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.